Clinical Trial Update: Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 2 results on the response rate of neoadjuvant docetaxel (Taxotere) in combination with trastuzumab for Nigerian women w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Taxotere (docetaxel)

Snippet

Sponsor: University of Chicago | Conditions: Breast Cancer, Breast Cancer Female | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-21